Dexcom

San Diego, United States Founded: 1999 • Age: 27 yrs Listed
Wearable glucose monitoring patches are provided for real-time data tracking.

About Dexcom

Dexcom is a publicly listed company based in San Diego (United States) founded in 1999. Wearable glucose monitoring patches are provided for real-time data tracking. It operates in the Healthcare and Technology sectors. Dexcom has raised $52.5 million across 8 funding rounds from investors including HHS, Warburg Pincus and Canaan. The company has 10,300 employees. Dexcom has completed 2 acquisitions, including SweetSpot Diabetes and TypeZero Technologies. Its chief executive, as recorded, is Kevin Sayer. Its website dexcom.com draws about 2.8 million monthly visits. Dexcom offers products and services including Dexcom G7 and Dexcom App. Its focus areas include Life Sciences, Diabetes, Medical Devices and Monitoring Devices. Its legal entity is Dexcom, Inc. Its competitors include Livongo, Senseonics and One Drop; 3 of its 3 listed competitors have raised funding.

Company details

Dexcom was founded in 1999 in San Diego, United States, and operates in the medical device sector focused on diabetes management. A wearable patch is offered that measures glucose levels continuously, with data transmitted wirelessly to a receiver or display device for real-time viewing. In 2022, revenues reached 3.02 billion, while net profit was recorded at 0.29 billion. The companys products support ongoing monitoring without frequent finger pricks.

  • Headquarters San Diego, United States
  • Employees 10,300
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Website category Health · Health Conditions and Concerns
  • Website dexcom.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Dexcom, Inc.
Key Metrics
  • Annual Revenue
    $4.66 B (USD)
    15.6
    as on Dec 31, 2025
  • Net Profit
    $836.3 M (USD)
    45.14
    as on Dec 31, 2025
  • EBITDA
    $1.16 B (USD)
    42.3
    as on Dec 31, 2025
  • Total Equity Funding
    $52.5M (USD)

    in 8 rounds

  • Latest Funding Round
    $1.05B (USD), Post-IPO

    Apr 2020

  • Investors
    HHS

    & 4 more

  • Employee Count
    10,300
  • Investments & Acquisitions

Products & Services of Dexcom

Dexcom offers a comprehensive portfolio of products and services, including Dexcom G7 and Dexcom App.

Dexcom G7
CGM System

Real-time glucose monitoring device that reduces fingerstick needs.

Dexcom App
Mobile Health Tool

App for viewing glucose data on smartphones and smartwatches.

Apps and channels of Dexcom

Dexcom publishes 3 mobile apps with over 2M+ downloads; its YouTube channel Dexcom Canada - English has 53 subscribers and 30 videos.

Dexcom Clarity
Google Play Health & Fitness Everyone Free
Developer: Dexcom
View on Google Play
Dexcom Clarity
App Store Medical 4+
Developer: Dexcom
View on App Store
Dexcom G7
Google Play Health & Fitness Everyone Free
Developer: Dexcom
View on Google Play
Dexcom Canada - English
YouTube 53 subscribers 30 videos Science & Technology
Open channel

Videos from Dexcom

The most watched videos on Dexcom's YouTube channel, Dexcom Canada - English (53 subscribers). Click a video to play it here.

Dexcom G7 – How to Insert the Sensor
68.7K views
How to Get Started and Set-up your Dexcom G7 App
44.6K views
Dexcom G7 System Walkthrough
11.1K views
Dexcom G7 How to Replace Your Dexcom G7 Sensor
10.8K views

More on Dexcom Canada - English.

Funding Insights of Dexcom

Dexcom has successfully raised a total of $52.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.05 billion completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $52.5M
  • Total Rounds 8
  • Last Round Post-IPO β€” $1.05B
  • First Round $30M

    (Jun 2002)

  • Investors Count 5

All 8 funding rounds of Dexcom with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2020$1.05BPost-IPO––
–
Dec 2018$850MPost-IPO––
–
May 2016$7.23MPost-IPO––
–
Sep 2014$224,354Grant––
Apr 2012$3.96MPost-IPO––
–
Feb 2005$235,498Debt – Convertible––
–
Jan 2005$22.5MSeries D––
Jun 2002$30MSeries C––
Valuation history

5 investors in total: 5 institutional.

Investors in Dexcom

Dexcom has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Warburg Pincus and Canaan.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Multi-stage private equity investments are pursued across diverse sectors.
1966warburgpincus.comNew York, United States
Canaan is recognized as an early-stage venture capital firm.
1987canaan.comSan Francisco, United States
Early-stage investments are made in US life-sciences and tech companies.
rwiventures.comMenlo Park, United States
Public health and human services are overseen by HHS.
1953hhs.gov
Fund based investment management firm and fund of funds focused on multiple sectors
1935invescomutualfund.comMumbai, India
Premium access

Investor details for Dexcom

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Dexcom

707 people are tracked at Dexcom (160 in leadership, 9 in board & advisors, 538 in team); the tracked headcount is 10,300.

NameRoleGroup
Kevin Sayer
CEO & PresidentLeadership
Terri Chera
Sr. Director Of Software Product And Technical Program Management At DexcomLeadership
Ryan Lindeman
Director Of Process EngineeringLeadership
Wendy Lundy
Staff TA Sourcing PartnerLeadership
Gabriel Altmayer
Director Of New Business Development & Strategic FinanceLeadership
Roxana Heitz
VP Of ProductLeadership
Matthew Johnson
Senior Director Clinical ScienceLeadership
Suyang Ooi
Senior Director Of EngineeringLeadership
Caitlin Taylor
Director Of ManufacturingLeadership
Jereme Sylvain
EVP & CFOLeadership
Joshua Windmiller
Head Of New Analytes And Sensing PlatformsLeadership
Mindy Kaur Sohal
Uk/emea Regional Business Partner, Talent Acquisition & EngagementLeadership
Mark Mydland
VP SW Development Engineering🔹lead 100+ Engineers🔹integrating AI With Mobile🔹speed With QualityLeadership
Jan Kupfer
Senior Director Legal EMEALeadership
Athena Pallares
Director Of Financial ReportingLeadership
Brennen Crawford
Finance Director - Global Revenue, Pricing, & ReportingLeadership
Aime Fausz
Director Of EngineeringLeadership
Michael Brown
Executive Vice President And Chief Legal OfficerLeadership
Donald Abbey
Executive Vice PresidentLeadership
Bhupesh Mahendru
Vice President Of Global Quality AssuranceLeadership

687 more people are available in the full profile.

Premium access

Complete people profiles for Dexcom

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Dexcom

Dexcom is a publicly listed company on the NASDAQ with ticker symbol DXCM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Apr 2005
  • Listed onNASDAQ: DXCM
  • Listed entityDexCom, Inc.
  • Exchange sectorHealth technology
  • ISINUS2521311074
  • Share price$85.06 (-1% on the day) · 2026-10-13
  • Market capitalisation$32.10B
  • Price to earnings33.6
  • EPS (diluted, trailing year)$2.53
  • Volume (last session)4,017,079

Financials of Dexcom

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$4.66B$836.3M$1.16B
2024$4.03B$576.2M$817.7M
2023$3.62B$541.5M$783.7M
2022$2.91B$341.2M$547.1M
2021$2.45B$216.9M$367.7M
Premium access

Detailed financial statements for Dexcom

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Dexcom

Dexcom has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include SweetSpot Diabetes and TypeZero Technologies.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Device for continuous glucose monitoring with manually operated insulin delivery
typezero.comCharlottesville, United States2013Aug 2018$11.3M
Platform to aggregate and analyze blood glucose data from devices
sweetspotdiabetes.comPortland, United States2009Feb 2012$8.5M
Premium access

Complete acquisition details for Dexcom

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Dexcom

6 dated milestones of Dexcom across 21 years, from founding to its latest funding, stage changes and deals.

  1. Founded Dexcom is founded.
  2. Funding First funding round of $30.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires SweetSpot Diabetes.
  5. Acquisition Acquires TypeZero Technologies.
  6. Funding Latest funding round, Post-IPO, of $1.1B.

Competitors of Dexcom

Dexcom has 3 listed competitors in our database, 3 of them funded. They include Livongo, Senseonics and One Drop.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
livongo.com2014San Francisco, United States$237M3,263
Provider of smart devices for diabetes management for patients and doctors
senseonics.com1996Germantown, United States$175.46M132
Implantable continuous glucose monitoring systems are provided for diabetes management.
onedrop.today2015New York, United States$107.87M166
Provider of workforce healthcare solutions
Premium access

Detailed competitors of Dexcom

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Dexcom

The website of Dexcom (dexcom.com) receives about 2.8M visits a month and ranks #19,957 among all websites worldwide, #428 in Health Conditions and Concerns.

  • Monthly visits
    2.8M

    ▲ 6.1% vs previous month

  • Unique visitors
    1.3M

    per month

  • Global rank
    #19,957

    among all websites

  • Category rank
    #428

    Health · Health Conditions and Concerns

Similar websites

Websites whose visitors overlap most with Dexcom. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
freestyle.abbott
freestyle.abbott
100%
#23,505–
libreview.com
84%
#50,343View details
medtronicdiabetes.com
medtronicdiabetes.com
78%
#198,048–
omnipod.com
76%
#42,515View details
diabetes.org
76%
1.4M#43,191View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 40 similar websites and full traffic analytics for Dexcom

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Diabetes

3 companies that operate in the same segment as Dexcom (Diabetes) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of devices for continuous glucose monitoring and manual insulin delivery
2008San Diego, California, United StatesUSD 100.73 MUSD 1.02 B2,650
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Small molecule drugs for various therapeutic areas are developed.
1995United StatesUSD 165 MUSD 49.8 M103
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Dexcom

Premium access

Complete news archive for Dexcom

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dexcom

Dexcom was founded in 1999 and raised its 1st funding round 3 years after it was founded.

Dexcom is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Kevin Sayer is the CEO of Dexcom, as recorded in our data.

Dexcom is a funded company, having raised a total of $52.5M across 8 funding rounds to date. The company's 1st funding round was a Series C of $30M, raised on Jun 2002.

Dexcom has 10,300 employees.

Annual revenue of Dexcom is $4.66B as on Dec 31, 2025.

Dexcom was founded in 1999 in San Diego, United States, and operates in the medical device sector focused on diabetes management. A wearable patch is offered that measures glucose levels continuously, with data transmitted wirelessly to a receiver or display device for real-time viewing. In 2022, revenues reached 3.02 billion, while net profit was recorded at 0.29 billion. The companys products support ongoing monitoring without frequent finger pricks.

Dexcom's top competitors include Senseonics, One Drop and Livongo.

Dexcom offers Dexcom G7 and Dexcom App.

Yes, Dexcom is publicly traded on NASDAQ under the ticker symbol DXCM.

Dexcom has made 2 acquisitions, including SweetSpot Diabetes, and TypeZero Technologies.

Dexcom has 5 investors. Key investors include HHS, Warburg Pincus, Canaan, Invesco Mutual Fund, and RWI Ventures.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available